PNPLA3 and metabolic dysfunction-associated steatohepatitis: Third, PNPLA3 148M expression in hepatic stellate cells is responsible for promoting fibrosis and interfering with retinol metabolism in the context of NASH and, therefore, any therapeutic agent must be able to target both hepatocytes and stellate cells.